TALQUETAMAB
Manufacturer: Janssen Biotech, Inc.
Score: 144.0
TALVEY is a bispecific GPRC5D-directed CD3 T-cell engager used for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. The drug has shown anti-tumor activity in mouse models of multiple myeloma and is administered via subcutaneous injection. Key clinical findings include response rate and durability of response, and important safety information includes warnings for cytokine release syndrome and neurologic toxicity. The main dosing recommendations involve a step-up dosing schedule and dose modifications for adverse reactions. Special population considerations include use during pregnancy, pediatric use, and geriatric use.
Cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, can occur with TALVEY
Dose modifications may be required for adverse reactions, including cytokine release syndrome, neurologic toxicity, and other adverse reactions
TALVEY 0.4 mg/kg weekly or 0.8 mg/kg every 2 weeks
Not established